Aurinia Pharmaceuticals Inc AUPH shares are down more than 20 percent Tuesday after nearly tripling in a month’s time. For traders wondering how the stock lost its mojo, the Twitter feed of TheStreet columnist Adam Feuerstein tells the story.
Related Link: 7 Tweets That Ruined Careers
The Aurinia rumors started at around 1 p.m. Monday, when Feuerstein reported hearing that the company intended to raise $100 million.
$AUPH looking to raise $100M, source tells me.
— Adam Feuerstein (@adamfeuerstein) March 13, 2017
A few minutes later, he got more specific, tweeting the deal could involve selling 15 million shares in the $6.25-$6.50 range.
$AUPH — hearing 15M shares offered at $6.25 to $6.75. Demand strong, could raise price.
— Adam Feuerstein (@adamfeuerstein) March 13, 2017
At 1:44 p.m., Feuerstein continued his tweetstorm by telling his followers Aurinia “is doing a great job raising money tonight.”
Please, please read this thread fro an investor pro so you’ll understand why $AUPH is doing a great job raising money tonight. https://t.co/w4honEFq24
— Adam Feuerstein (@adamfeuerstein) March 13, 2017
When followers criticized his take on the pricing of the deal, Feuerstein fired back.
Yes. Long-term, fundamental investors buying $AUPH deal aren’t paying a premium for your momentum-fueled trading. https://t.co/V8FCfIf6qX
— Adam Feuerstein (@adamfeuerstein) March 13, 2017
On Tuesday morning, he reported that the offering had officially been upsized to 22.3 million shares at $6.75/share.
$AUPH upsized its offering to 22.3M shares. Priced at $6.75. Brings in $150M.
— Adam Feuerstein (@adamfeuerstein) March 14, 2017
Excellent work, guys.
While the stock may have lost its short-term momentum following the offering, Feuerstein believes the fundraising and the price were excellent for long-term investors. He concluded his tweetstorm with a shout out to all the people who doubted his motives on Monday afternoon.
To my Twitter fans who accused me of being manipulative or lying last night when I told you the $AUPH pricing. pic.twitter.com/GgdkIhY3tp
— Adam Feuerstein (@adamfeuerstein) March 14, 2017
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.